The Comparison of Efficacy of Original Brand Deferoxamine with Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients with Thalassemia Major
Journal Title: Iranian Journal of Blood and Cancer - Year 2017, Vol 9, Issue 4
Abstract
Background: Deferoxamine mesylate is still the conventional and well-known iron chelator for patients with thalassemia major. However, due to some marketing issues the well-known original brand, Desferal®, produced by Novartis Pharmaceuticals Company is not as available as before. The generic brands of Deferoxamine have been introduced in many parts of the world including Iran; however, they are not well accepted by the physicians and patients yet. This triple-blind randomized controlled trial was designed to compare the efficacy and safety of a new Iranian generic and the original brand product of Deferoxamine mesylate in Iranian patients. Methods: The present Randomized triple-blind controlled trial research was carried on in nine centers throughout Iran. They were randomly divided into two similar groups and a Cross-over study was designed. 24-hour urine was collected after subcutaneous infusion of either drugs and urinary iron excretion was measured via atomic absorption spectrophotometer device. Acute adverse events during and after drug infusion were recorded. Mack Nara test and p-pair test were applied to compare two cross over interventions. Results: 154 patients from 9 centers were enrolled in this study. There were 95 women and 59 men aged 6-34 years (mean age of 21.1years). Mean urinary iron concentration for Desferal (intervention A) vs. Desfonak (intervention B) groups was 22.5±22.6 vs. 21.5±16.9 mg/m2 , respectively. Mean urinary iron excretion/Kg body weight for Desferal (intervention A) vs. Desfonak (intervention B) groups was 0.48±0.48 vs. 0.47±0.40 mg/m2, respectively. Conclusion: According to the results of this study, there was similarity between efficacy and safety of the original and generic brands of deferoxamine (desferal vs. desfonac).
Authors and Affiliations
Peyman Eshghi, Ali Amin Asnafi, Ahmadreza Shamshiri, Samin Alavi, Mohammad Molavi, Ahmad Tamaddoni, Bijan Keikhaie, Majid Naderi, Hamid Hoorfar, Shahla Ansari, Azita Azarkeivan, Zahra Kourorian
Keywords
Related Articles
- EP ID EP281304
- DOI -
- Views 115
- Downloads 0
A Rare Presentation of Arterial Thrombosis after Venous Thrombosis in a Patient with Gastric Cancer
Background: Venous thromboembolism, which comprises deep vein thrombosis and pulmonary embolism and is a significant cause of morbidity and mortality among patients with cancer. The aim of the present study was to report...
Infusible Platelet Membrane versus Conventional Platelet Concentrate: Benefits and Disadvantages
Blood transfusion centers are under considerable pressure to produce platelet concentrates with a shelf life limit of 3 to 5 days. Many approaches have been investigated experimentally to produce new hemostatically activ...
A Bibliometric Analysis of Hematological Research Productivity among Five Islamic Countries during 1996 to 2013 (a 17-years period)
Background: This study made an attempt to make the quantitative and qualitative evaluation of hematological research output in five Islamic countries Iran, Turkey, Malaysia, Saudi Arabia and Egypt which have the most sci...
Leptin in Breast Cancer: Its Relationship with Insulin, Estrogens and Oxidative Stress
Breast cancer is the most common cancer in women. Several risk factors such as age, family history of breast cancer, marital status, early menarche and late menopause are related to breast cancer. Obesity is also a main...
Neuroendocrine Carcinoma of the Stomach A Case Report
Gastric neuroendocrine carcinoma is a rare tumor which has a poor prognosis. Herein, we present a 55-year-old woman who presented with complaints of recurrent vomiting, hematemesis and weight loss. Endoscopic examination...